Diagnosis and management of growth hormone deficiency in adults

Endocrinology and Metabolism Clinics of North America

Volumn 30, Issue 3, 2001, Pages 545-563

  Stavrou, S ^a   Kleinberg, D L ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOCORTICOID; GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN; SOMATOMEDIN C;

ARTHRALGIA; BODY COMPOSITION; BRAIN INJURY; BRAIN RADIATION; CARDIOVASCULAR RISK; CARPAL TUNNEL SYNDROME; CLINICAL EXAMINATION; DIFFERENTIAL DIAGNOSIS; EDEMA; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HEART FUNCTION; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS TUMOR; LIPID METABOLISM; MORTALITY; MYALGIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; WELLBEING;

EID: 0034849173     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70201-2     Document Type: Article

References (144)

1. The specificity of growth hormone stimulation tests in childhood and adolescence
2. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency
3. GH replacement in 1034 growth hormone deficient hypopituitary adults: Demographic and clinical characteristics, dosing and safety
4. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults
5. Usefulness of IGF-I assay for the diagnosis of GH deficiency in adults
6. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses
7. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: Dependence on serum LDL levels
8. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment
9. The effect of hypopituitarism on life expectancy
10. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency
11. Effects of physiologic growth hormone therapy on bone mineral density and body composition in patients with adult-onset growth hormone deficiency
12. Mutations in the growth hormone releasing hormone receptor: A new form of dwarfism in humans
13. The dwarfs of Sindh: Severe growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene
14. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH
15. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults: KIMS Study Group and the KIMS International Board
16. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH
17. The effects of short and long term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance
18. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism
19. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: Correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3
20. Body composition in growth hormone-deficient adults
21. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition
22. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience
23. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency
24. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: A prospective study
25. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer
26. Hypopituitary females have a high incidence of cardiovascular morbidity and increased prevalence of cardiovascular risk factors
27. Increased cerebrovascular mortality in patients with hypopituitarism
28. Cardiovascular and renal effects of growth hormone
29. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
30. Lung carcinoma associated with production of three placental proteins
31. The safety profile of GH replacement therapy in adults
32. Growth hormone state after completion of treatment with growth hormone
33. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism
34. Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidaemia of adult growth hormone deficiency
35. Growth hormone treatment in growth hormone-deficient adults: Effects on exercise performance
36. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-deficient adults
37. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency
38. Growth hormone treatment in growth hormone-deficient adults: I. Effects on muscle mass and strength
39. Skeletal muscle performance in adults with growth hormone deficiency
40. Clinical aspects of growth hormone deficiency in adults
41. The consequences of childhood-onset growth hormone deficiency for adult bone mass
42. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis
43. Serum lipid levels in growth hormone deficient men
44. Reduced bone mineral density in adults with growth hormone deficiency: Increased bone turnover during 12 months of GH substitution therapy
45. The development of the AGHDA score: A measure to assess quality life of adults with growth hormone deficiency
46. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults
47. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations
48. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency
49. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease
50. Growth hormone replacement does not improve psychological well-being in adult hypopituitarism: A randomized crossover trial
51. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency
52. Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: Comparison with insulin-induced hypoglycemia test
53. New approach to the diagnosis of growth hormone deficiency in adults
54. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients
55. Urinary growth hormone (GH), insulin-like growth factor I (IGF-I), and IGF-binding protein-3 measurements in the diagnosis of adult GH deficiency
56. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
57. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: A double blind, randomized, placebo-controlled study
58. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?
59. The role of human hormone in the regulation of cholesterol and bile acid metabolism
60. Insulin resistance in growth hormone-deficient adults: Defects in glucose utilization and glycogen synthase activity
61. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects
62. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: Importance of endogenous estradiol concentrations
63. Diagnosis of growth hormone deficiency in adults
64. Reduced bone mineral density in patients with adult onset growth hormone deficiency
65. Which adults develop side-effects of growth hormone replacement?
66. Effects of growth hormone replacement therapy in adults with severe growth hormone deficiency
67. Growth hormone deficiency during puberty reduces adult bone mineral density
68. A low starting dose of genotropin in growth hormone-deficient adults
69. Discontinuation of growth hormone (GH) treatment: Metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects
70. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults
71. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency
72. Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults
73. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency
74. Growth hormone-deficient adults are insulin-resistant
75. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults
76. Long-term growth hormone treatment in growth hormone deficient adults
77. Beneficial effects of growth hormone treatment in GH-deficient adults
78. Three years of growth hormone treatment in growth hormone-deficient adults: Near normalization of body composition and physical performance
79. Determinants of serum insulin-like growth factor I in growth hormone deficient adults as compared to healthy subjects
80. Beneficial effects of growth hormone treatment in GH-deficient adults
81. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3
82. Normal bone mineral density in patients with adult onset GH deficiency
83. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults
84. Bone mineral status in growth hormone deficient males with isolated and multiple pituitary deficiencies of childhood onset
85. How many tests are required to diagnose growth hormone (GH) deficiency in adults?
86. Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency
87. Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood
88. Growth hormone, insulin-like growth factor I, and benign intracranial hypertension
89. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults
90. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency
91. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency
92. Decreased plasma and extracellular volume in growth hormone deficient adults and the acute and prolonged effects of GH administration: A controlled experimental study
93. Brain tumor recurrence in children treated with growth hormone: The National Cooperative Growth Study experience
94. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults
95. Effects of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood
96. Adult growth hormone deficiency
97. The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood
98. Isolated human growth hormone deficiency due to the hGH-I gene deletion with (type IA) and without (the Israeli-type) hGH antibody formation during hGH therapy
99. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH defiency
100. The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: A minimal model analysis
101. Mutations in the Pit-1 gene in children with combined pituitary hormone deficiency
102. Mortality and cancer incidence in acromegaly: A retrospective cohort study
103. Genes regulating hypothalamic and pituitary development
104. Heritable disorders of pituitary development
105. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia
106. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults
107. Insulin-like growth factors and prostate cancer
108. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults
109. A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency
110. Serum collagen crosslinks as markers of bone turn-over during GH replacement therapy in growth hormone deficient adults
111. Premature mortality due to cardiovascular disease in hypopituitarism
112. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency
113. Cardiovascular risk factors in adult patients with growth hormone deficiency
114. Reduced bone mineral content in patients with growth hormone deficiency
115. Decreased psychological well-being in adult patients with growth hormone deficiency
116. Changes in skeletal muscle and body composition after discontinuation of growth hormone treatment in growth hormone deficient young adults
117. Glucose metabolism in adults with growth hormone deficiency
118. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
119. Growth hormone replacement therapy during transition of patients with childhood-onset growth hormone deficiency into adulthood: What are the issues?
120. Paying the price for cure-treating cancer survivors with growth hormone
121. Insulin-like growth factor-I in growth hormone-deficient adults: Relationship to population-based normal values, body composition and insulin tolerance test
122. Growth hormone treatment of children with brain tumors and risk of tumor recurrence
123. Mortality in Canadian children with growth hormone (GH) deficiency receiving GH therapy 1967-1992: The Canadian Growth Hormone Advisory Committee
124. Brief report: Short stature caused by a mutant growth hormone
125. Cretinism with combined hormone deficiency caused by a mutation in the PIT1 gene
126. Growth hormone retesting and auxological data in 131 GH-deficient patients after completion of treatment
127. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency
128. The diagnosis of growth hormone deficiency (GHD) in adults
129. Serum insulin-like growth factor-I and breast cancer
130. Elderly patients with adult-onset growth hormone deficiency are not osteopenic
131. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism
132. The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity: A 12-month placebo-controlled study
133. Cardiac performance and mass in adults with hypopituitarism: Effects of 1 year of growth hormone treatment
134. Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan
135. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males
136. Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth
137. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults
138. The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults
139. Growth hormone treatment of adults with growth hormone deficiency: Results of a 13-month placebo controlled cross-over study
140. Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency
141. Insulin-like growth factor 1 and prostate cancer risk: A population-based case-control study
142. Mutations in PROP1 cause familial combined pituitary hormone deficiency
143. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density: The KIMS Study Group and the KIMS International Board
144. Increased prevalence of osteoporosis and arteriosclerosis in patients with conventionally substituted pituitary insufficiency: Is there a need for additional growth hormone substitution?